Company Overview
Sales
196
Cr
Growth: 10.3%
Profit after Tax
24.9
Cr
Growth:
36.8%
Micro Cap
153
Cr
P/E:
5.4x
Industry P/E: 36.7x
Fundamentals
| Sales (Cr) |
₹ 196 |
| Growth |
10.3% |
| EBITDA |
19.0% |
| P/S |
0.8x |
| Dividend |
0.0% |
| P/E |
5.4x |
| Book Value |
₹ 1,337 |
| PEG Ratio |
0.5x |
| ROE |
25.7% |
| P/B |
1.4x |
Shareholding Pattern
Institutions
Promoters
Emami Infrastructure Limited
35.51
%
Others
Bpc Tradecom Pvt Ltd
2.6
%
Increase
Decrease
No change
Zandu Pharmaceutical works name was changed to Zandu Realty from March 10, 2010. At present, the company is a multi-product entity, comprising a group of companies. Zandu projects a sale of nearly Rs. 2,000/- Million by 2000 A.D.It was listed in 1919; is engaged in offering ayurvedic healthcare medicines. Zandu manufactures a wide range of ayurvedic medicine specialised in area of rheumatology, gynaecology and CNS (Central nervous system).
